For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses. Loss-making companies are always racing against time to reach financial sustainability, so investors in these companies may be taking on more risk than they should.
Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like Cell Bio Human TechLtd (KOSDAQ:318160). Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business.
In the last three years Cell Bio Human TechLtd's earnings per share took off; so much so that it's a bit disingenuous to use these figures to try and deduce long term estimates. So it would be better to isolate the growth rate over the last year for our analysis. Outstandingly, Cell Bio Human TechLtd's EPS shot from ₩686 to ₩1,262, over the last year. It's not often a company can achieve year-on-year growth of 84%. That could be a sign that the business has reached a true inflection point.
Top-line growth is a great indicator that growth is sustainable, and combined with a high earnings before interest and taxation (EBIT) margin, it's a great way for a company to maintain a competitive advantage in the market. While Cell Bio Human TechLtd did well to grow revenue over the last year, EBIT margins were dampened at the same time. If EBIT margins are able to stay balanced and this revenue growth continues, then we should see brighter days ahead.
In the chart below, you can see how the company has grown earnings and revenue, over time. To see the actual numbers, click on the chart.
View our latest analysis for Cell Bio Human TechLtd
Cell Bio Human TechLtd isn't a huge company, given its market capitalisation of ₩42b. That makes it extra important to check on its balance sheet strength.
Theory would suggest that it's an encouraging sign to see high insider ownership of a company, since it ties company performance directly to the financial success of its management. So as you can imagine, the fact that Cell Bio Human TechLtd insiders own a significant number of shares certainly is appealing. Actually, with 42% of the company to their names, insiders are profoundly invested in the business. Those who are comforted by solid insider ownership like this should be happy, as it implies that those running the business are genuinely motivated to create shareholder value. Valued at only ₩42b Cell Bio Human TechLtd is really small for a listed company. That means insiders only have ₩17b worth of shares, despite the large proportional holding. That might not be a huge sum but it should be enough to keep insiders motivated!
Cell Bio Human TechLtd's earnings have taken off in quite an impressive fashion. That sort of growth is nothing short of eye-catching, and the large investment held by insiders should certainly brighten the view of the company. The hope is, of course, that the strong growth marks a fundamental improvement in the business economics. So based on this quick analysis, we do think it's worth considering Cell Bio Human TechLtd for a spot on your watchlist. Before you take the next step you should know about the 2 warning signs for Cell Bio Human TechLtd (1 makes us a bit uncomfortable!) that we have uncovered.
Although Cell Bio Human TechLtd certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see companies with more skin in the game, then check out this handpicked selection of South Korean companies that not only boast of strong growth but have strong insider backing.
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.